{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:54:33Z","timestamp":1777395273864,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2021,4,20]]},"abstract":"<jats:p>Background: Imaging biomarkers have the potential to distinguish between different brain pathologies based on the type of ligand used with PET. AV-45 PET (florbetapir, Amyvid\u2122) is selective for the neuritic plaque amyloid of Alzheimer\u2019s disease (AD), while AV-133 PET (florbenazine) is selective for VMAT2, which is a dopaminergic marker. Objective: To report the clinical, AV-133 PET, AV-45 PET, and neuropathological findings of three clinically diagnosed dementia patients who were part of the Avid Radiopharmaceuticals AV133-B03 study as well as the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND). Methods: Three subjects who had PET imaging with both AV-133 and AV-45 as well as a standardized neuropathological assessment were included. The final clinical, PET scan, and neuropathological diagnoses were compared. Results: The clinical and neuropathological diagnoses were made blinded to PET scan results. The first subject had a clinical diagnosis of dementia with Lewy bodies (DLB); AV-133 PET showed bilateral striatal dopaminergic degeneration, and AV-45 PET was positive for amyloid. The final clinicopathological diagnosis was DLB and AD. The second subject was diagnosed clinically with probable AD; AV-45 PET was positive for amyloid, while striatal AV-133 PET was normal. The final clinicopathological diagnosis was DLB and AD. The third subject had a clinical diagnosis of DLB. Her AV-45 PET was positive for amyloid and striatal AV-133 showed dopaminergic degeneration. The final clinicopathological diagnosis was multiple system atrophy and AD. Conclusion: PET imaging using AV-133 for the assessment of striatal VMAT2 density may help distinguish between AD and DLB. However, some cases of DLB with less-pronounced nigrostriatal dopaminergic neuronal loss may be missed.<\/jats:p>","DOI":"10.3233\/jad-200323","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T12:58:14Z","timestamp":1615294694000},"page":"1603-1612","source":"Crossref","is-referenced-by-count":5,"title":["Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer\u2019s Disease or Dementia with Lewy Bodies"],"prefix":"10.1177","volume":"80","author":[{"given":"Harsh V.","family":"Gupta","sequence":"first","affiliation":[{"name":"Department of Neurology, The University of Kansas Health System, Kansas City, KS, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas G.","family":"Beach","sequence":"additional","affiliation":[{"name":"Banner Sun Health Research Institute, Sun City, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyamal H.","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly A.","family":"Shill","sequence":"additional","affiliation":[{"name":"Barrow Neurological Institute, Phoenix, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Driver-Dunckley","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan N.","family":"Sabbagh","sequence":"additional","affiliation":[{"name":"Ruvo Clinic, Las Vegas, NV, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine M.","family":"Belden","sequence":"additional","affiliation":[{"name":"Banner Sun Health Research Institute, Sun City, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn","family":"Liebsack","sequence":"additional","affiliation":[{"name":"Banner Sun Health Research Institute, Sun City, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany N.","family":"Dugger","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of California-Davis School of Medicine, Sacramento, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geidy E.","family":"Serrano","sequence":"additional","affiliation":[{"name":"Banner Sun Health Research Institute, Sun City, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia I.","family":"Sue","sequence":"additional","affiliation":[{"name":"Banner Sun Health Research Institute, Sun City, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Siderowf","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Pontecorvo","sequence":"additional","affiliation":[{"name":"Avid Radiopharmaceuticals, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Mintun","sequence":"additional","affiliation":[{"name":"Avid Radiopharmaceuticals, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinay D.","family":"Joshi","sequence":"additional","affiliation":[{"name":"Avid Radiopharmaceuticals, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles H.","family":"Adler","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic College of Medicine, Scottsdale, AZ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-200323_ref1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000334535","article-title":"Differential diagnosis in Alzheimer\u2019s disease and dementia with Lewy bodies via VMAT2 and amyloid imaging","volume":"10","author":"Villemagne","year":"2012","journal-title":"Neurodegener Dis"},{"key":"10.3233\/JAD-200323_ref2","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1212\/WNL.0000000000000641","article-title":"Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study","volume":"83","author":"Adler","year":"2014","journal-title":"Neurology"},{"key":"10.3233\/JAD-200323_ref3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/NEN.0b013e31824b211b","article-title":"Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005\u20132010","volume":"71","author":"Beach","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-200323_ref4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00415-009-5324-y","article-title":"Low sensitivity in clinical diagnoses of dementia with Lewy bodies","volume":"257","author":"Nelson","year":"2010","journal-title":"J Neurol"},{"key":"10.3233\/JAD-200323_ref5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3233\/JAD-2010-091504","article-title":"Pre-clinical detection of Alzheimer\u2019s disease using FDG-PET, with or without amyloid imaging","volume":"20","author":"Mosconi","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200323_ref6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1474-4422(12)70142-4","article-title":"Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: A prospective cohort study","volume":"11","author":"Clark","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-200323_ref7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2014.4144","article-title":"Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density","volume":"72","author":"Curtis","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.3233\/JAD-200323_ref8","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jalz.2015.02.004","article-title":"Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer\u2019s disease: Phase 3 study","volume":"11","author":"Sabri","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200323_ref9","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1097\/NEN.0000000000000114","article-title":"Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of Alzheimer dementia and detection of preclinical cortical amyloid","volume":"73","author":"Beach","year":"2014","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-200323_ref10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/jama.2010.2017","article-title":"Mapping out biomarkers for Alzheimer disease","volume":"305","author":"Breteler","year":"2011","journal-title":"JAMA"},{"key":"10.3233\/JAD-200323_ref11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cpet.2010.02.001","article-title":"(18)F-AV-133: A delective VMAT2-binding radiopharmaceutical for PET imaging of dopaminergic neurons","volume":"5","author":"Hefti","year":"2010","journal-title":"PET Clin"},{"key":"10.3233\/JAD-200323_ref12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2967\/jnumed.109.070094","article-title":"In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133","volume":"51","author":"Okamura","year":"2010","journal-title":"J Nucl Med"},{"key":"10.3233\/JAD-200323_ref13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-2377-14-79","article-title":"PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer\u2019s disease and Lewy body disorders","volume":"14","author":"Siderowf","year":"2014","journal-title":"BMC Neurol"},{"key":"10.3233\/JAD-200323_ref14","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","article-title":"Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology"},{"key":"10.3233\/JAD-200323_ref15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"10.3233\/JAD-200323_ref16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/neup.12189","article-title":"Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program","volume":"35","author":"Beach","year":"2015","journal-title":"Neuropathology"},{"key":"10.3233\/JAD-200323_ref17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00401-009-0538-8","article-title":"Unified staging system for Lewy body disorders: Correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction","volume":"117","author":"Beach","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-200323_ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: A practical approach","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-200323_ref19","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.1212\/WNL.0000000000007855","article-title":"Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease","volume":"93","author":"Shirvan","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JAD-200323_ref20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","article-title":"Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium","volume":"89","author":"McKeith","year":"2017","journal-title":"Neurology"},{"key":"10.3233\/JAD-200323_ref21","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/jnnp.2006.110122","article-title":"Dementia with Lewy bodies: A comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy","volume":"78","author":"Walker","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.3233\/JAD-200323_ref22","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1212\/01.wnl.0000306697.48738.b6","article-title":"Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort","volume":"70","author":"Zaccai","year":"2008","journal-title":"Neurology"},{"key":"10.3233\/JAD-200323_ref23","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1093\/brain\/aws211","article-title":"Neuropathological correlates of dopaminergic imaging in Alzheimer\u2019s disease and Lewy body dementias","volume":"135","author":"Colloby","year":"2012","journal-title":"Brain"},{"key":"10.3233\/JAD-200323_ref24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jnen\/63.4.329","article-title":"Substantia nigra Marinesco bodies are associated with decreased striatal expression of dopaminergic markers","volume":"63","author":"Beach","year":"2004","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-200323_ref25","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/brain\/awr089","article-title":"Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography","volume":"134","author":"Burke","year":"2011","journal-title":"Brain"},{"key":"10.3233\/JAD-200323_ref26","doi-asserted-by":"crossref","first-page":"e0217566","DOI":"10.1371\/journal.pone.0217566","article-title":"Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease","volume":"14","author":"Malek-Ahmadi","year":"2019","journal-title":"PLoS One"},{"key":"10.3233\/JAD-200323_ref27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.parkreldis.2014.02.012","article-title":"Concomitant pathologies among a spectrum of parkinsonian disorders.","volume":"20","author":"Dugger","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.3233\/JAD-200323_ref28","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/mds.25975","article-title":"Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts","volume":"29","author":"Kraemmer","year":"2014","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-200323_ref29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/mds.24000","article-title":"Dopamine transporter imaging in autopsy-confirmed Parkinson\u2019s disease and multiple system atrophy","volume":"27","author":"Perju-Dumbrava","year":"2012","journal-title":"Mov Disord"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-200323","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:05:20Z","timestamp":1777370720000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-200323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":29,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jad-200323","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]}}}